Table 1.
Patient and tumor characteristics
| Variable | Total (n=438) |
|---|---|
| Age, years | 57.0 (51.0-67.0) |
| ECOG PS | |
| 0 | 364 (83.1) |
| 1-2 | 66 (15.1) |
| 3-4 | 8 (1.8) |
| Gender | |
| Female | 55 (12.6) |
| Male | 383 (87.4) |
| Etiology | |
| HBV | 293 (66.9) |
| HCV | 17 (3.9) |
| HBV/HCV | 7 (1.6) |
| Non-viral | 121 (27.6) |
| Alcoholic liver disease | 40 (9.1) |
| Not specified | 81 (18.5) |
| Child-Pugh class | |
| A | 357 (81.5) |
| B | 69 (15.8) |
| C | 12 (2.7) |
| ALBI score | -2.7 (-3.0 to -2.3) |
| modified ALBI | |
| Grade 1 | 244 (55.7) |
| Grade 2a | 91 (20.8) |
| Grade 2b | 89 (20.3) |
| Grade 3 | 14 (3.2) |
| AFP, ng/mL | 882.5 (28.5-21,013.7) |
| PIVKA-II, mAU/mL | 8,530.0 (1,306.0-40,429.0) |
| Presentation | |
| Solitary | 166 (37.9) |
| Multiple | 233 (53.2) |
| Diffuse | 39 (8.9) |
| Tumor size, cm | 15.0 (9.8-15.0) |
| >5, <10 | 141 (32.2) |
| ≥10 | 297 (67.8) |
| Vascular invasion | |
| Hepatic vein | 57 (13.0) |
| Inferior vena cava | 3 (0.7) |
| Bile duct invasion | |
| Present | 22 (5.0) |
| PVTT classification | |
| Vp0 | 182 (41.6) |
| Vp1 | 17 (3.9) |
| Vp2 | 48 (11.0) |
| Vp3 | 67 (15.3) |
| Vp4 | 124 (28.3) |
| LN metastasis | |
| Present | 78 (17.8) |
| mUICC stage | |
| Stage II | 84 (19.2) |
| Stage III | 119 (27.2) |
| Stage IVA | 134 (30.6) |
| Stage IVB | 101 (23.1) |
| BCLC stage | |
| A | 80 (18.3) |
| B | 37 (8.4) |
| C | 303 (69.2) |
| D | 18 (4.1) |
Values are presented as patient number (%) or median (interquartile range).
ECOG PS, Eastern Cooperative Oncology Group performance status; HBV, hepatitis B virus; HCV, hepatitis C virus; ALBI, albumin-bilirubin score; AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K absence-II; PVTT, portal vein tumor thrombosis; LN, lymph node; mUICC, modified International Union Against Cancer; BCLC, Barcelona Clinic Liver Cancer.